Kim Jon Soo, Kim Hunmin, Lim Byung Chan, Chae Jong-Hee, Choi Jieun, Kim Ki Joong, Hwang Yong Seung, Hwang Hee
Department of Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea; Department of Pediatrics, Eulji University Hospital, Dae-jeon, Republic of Korea.
Department of Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea.
Brain Dev. 2014 Jun;36(6):510-5. doi: 10.1016/j.braindev.2013.07.003. Epub 2013 Aug 12.
To evaluate the efficacy and safety of lacosamide in pediatric patients with refractory focal epilepsy.
We reviewed retrospectively the medical records of children younger than 18 years of age treated at Seoul National University Bundang Hospital, in whom oral lacosamide was used as an adjunctive treatment for refractory focal epilepsy. Clinical information regarding the patients' epilepsy and the outcome of lacosamide treatment was gathered and analyzed.
Twenty-one patients (16 boys, 5 girls) were included, with a median age of 13.9 (range, 1.2-17.9) years. The mean number of concomitant antiepileptic drugs was 3.0 (range, 1-6) and the mean duration of follow-up was 10.1 (range, 6.1-13.0) months. The mean maintenance dose of lacosamide was 5.4 (range, 1.4-9.8) mg/kg/day. Fourteen patients (67%) were responders; four of these were seizure free at the last follow-up. Seven patients (33%) were nonresponders: two of these presented with <50% seizure reduction and five showed no change in seizure frequency. Two patients (10%) discontinued oral lacosamide because of adverse events (aggressive behavior and depression). Mild transient treatment-related adverse events were observed in eight of the 21 patients (38%).
Lacosamide represents a useful drug that is effective for a wide range of pediatric refractory focal epilepsy and is well tolerated.
评估拉科酰胺治疗难治性局灶性癫痫患儿的疗效和安全性。
我们回顾性分析了首尔国立大学盆唐医院收治的18岁以下使用口服拉科酰胺作为难治性局灶性癫痫辅助治疗的患儿的病历。收集并分析了有关患者癫痫及拉科酰胺治疗结果的临床信息。
纳入21例患者（16例男孩，5例女孩），中位年龄为13.9岁（范围1.2 - 17.9岁）。抗癫痫药物的平均联用数量为3.0种（范围1 - 6种），平均随访时间为10.1个月（范围6.1 - 13.0个月）。拉科酰胺的平均维持剂量为5.4 mg/kg/天（范围1.4 - 9.8 mg/kg/天）。14例患者（67%）有反应；其中4例在最后一次随访时无癫痫发作。7例患者（33%）无反应：其中2例癫痫发作减少<50%，5例癫痫发作频率无变化。2例患者（10%）因不良事件（攻击行为和抑郁）停用口服拉科酰胺。21例患者中有8例（38%）观察到轻度短暂的治疗相关不良事件。
拉科酰胺是一种有效的药物，对多种小儿难治性局灶性癫痫有效且耐受性良好。
